Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01BVI
|
||||
| Former ID |
DIB016550
|
||||
| Drug Name |
V-101
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Erythema [ICD9: 695; ICD10:L51-L54] | Phase 2 | [1] | ||
| Company |
Vicept Therapeutics Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H6Cl4S
|
||||
| Canonical SMILES |
C1=CC(=CC=C1SC2=CC(=C(C=C2Cl)Cl)Cl)Cl
|
||||
| InChI |
1S/C12H6Cl4S/c13-7-1-3-8(4-2-7)17-12-6-10(15)9(14)5-11(12)16/h1-6H
|
||||
| InChIKey |
QUWSDLYBOVGOCW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
6117681, 8162500, 24862557, 29217921, 29284519, 48413449, 49857254, 57329472, 57649564, 75227897, 104340503, 124489704, 124893233, 126409829, 129078622, 134983333, 137012811, 144209590, 144213301, 162252226, 164817940, 165373836, 176263564, 184583685, 198976120, 223447082, 223518516, 226414346, 241238158, 242176395, 250101386, 252329535
|
||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01186068) Dose Response Study of Patients With Erythematous Rosacea. U.S. National Institutes of Health. | ||||
| REF 2 | Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012 Dec;17(10):1-4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.